Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk

Dow Jones

Jul 22, 2025

0845 GMT - Sanofi's deal to buy U.K. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help Sanofi offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 22, 2025 04:45 ET (08:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553235152"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553235152\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553235152?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553235152","market":"hk","top_or_hot":-1,"title":"Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0845 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s deal to buy U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 04:45 ET (08:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-22 16:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0845 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s deal to buy U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 04:45 ET (08:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553235152","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553235152","pubTimestamp":1753173900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0845 GMT - Sanofi's deal to buy U.K. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help Sanofi offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"赛诺菲收购Vicebio可以弥补管道挫折——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1},"content_text":"0845 GMT - Sanofi's deal to buy U.K. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help Sanofi offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 22, 2025 04:45 ET (08:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}